STOCK TITAN

Biodesix, Inc. - BDSX STOCK NEWS

Welcome to our dedicated page for Biodesix news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on Biodesix stock.

Biodesix, Inc. (BDSX) is a trailblazing diagnostic solutions company specialized in the development and commercialization of blood-based molecular diagnostic tests. These tests advance the standard of care in oncology by providing invaluable data to help patients and their doctors make more informed decisions based on a patient's unique molecular profile. This approach is at the heart of precision medicine, aiming to provide the right treatment to the right patient at the right time.

The company is particularly focused on lung disease and operates in a single segment dedicated to providing diagnostic testing services. Biodesix partners with pharmaceutical companies to develop and commercialize diagnostic tests that accelerate drug development pipelines and bring effective therapies to the market.

Among its notable products are two commercialized tests, VeriStrat® and GeneStrat™, which offer rapid results within 72 hours and do not require tissue samples. These tests enable quicker and more precise treatment decisions, facilitating optimal patient care.

Biodesix's revenue streams come from two primary sources: providing diagnostic testing services related to blood-based lung and COVID-19 tests, and offering biopharmaceutical companies services for diagnostic research, clinical trial testing, and companion diagnostics development. These services are generally performed outside the clinical setting and are governed by individual contracts with third parties.

Recently, Biodesix has been in the news for various significant developments. The latest updates highlight the company's ongoing projects, partnerships, and achievements in the diagnostic field. Stay tuned for more updates as Biodesix continues to innovate in precision medicine and diagnostic solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences earnings
-
Rhea-AI Summary
Biodesix, Inc. announced that the ORACLE study achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures. The study showed that patients with benign nodules managed with the Nodify XL2 test were 74% less likely to undergo an unnecessary invasive procedure compared to the control group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
-
Rhea-AI Summary
Biodesix, Inc. announced that the Nodify CDT Test has been designated as an Advanced Diagnostic Laboratory Test (ADLT) by CMS, effective June 30, 2023. The Nodify CDT test is used in combination with the Nodify XL2 test for lung cancer diagnosis and treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.63%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.79%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.28%
Tags

FAQ

What is the current stock price of Biodesix (BDSX)?

The current stock price of Biodesix (BDSX) is $1.28 as of November 22, 2024.

What is the market cap of Biodesix (BDSX)?

The market cap of Biodesix (BDSX) is approximately 184.7M.

What does Biodesix, Inc. specialize in?

Biodesix specializes in blood-based molecular diagnostic tests that advance care in oncology, focusing primarily on lung disease.

What are some of Biodesix's key products?

Biodesix's key products include VeriStrat® and GeneStrat™, which provide rapid test results within 72 hours without needing tissue samples.

How does Biodesix contribute to precision medicine?

Biodesix contributes to precision medicine by helping physicians provide the right treatment to the right patient at the right time, based on the patient's unique molecular profile.

What services does Biodesix provide to biopharmaceutical companies?

Biodesix provides diagnostic research, clinical trial testing, and the development and commercialization of companion diagnostics to biopharmaceutical companies.

What are Biodesix's primary revenue sources?

Biodesix's revenue mainly comes from providing diagnostic testing services for blood-based lung and COVID-19 tests and offering services to biopharmaceutical companies.

How quickly can Biodesix's tests provide results?

Biodesix's tests, such as VeriStrat® and GeneStrat™, offer results within 72 hours.

Does Biodesix require tissue samples for its tests?

No, Biodesix's tests do not require tissue samples.

What recent achievements has Biodesix made?

Biodesix has recently been in the news for its ongoing projects, partnerships, and significant advancements in diagnostic solutions.

Is Biodesix focused solely on oncology diagnostics?

While Biodesix focuses heavily on oncology diagnostics, it also provides COVID-19 testing services.

What is the ticker symbol for Biodesix, Inc. on the stock market?

The ticker symbol for Biodesix, Inc. is BDSX.

Biodesix, Inc.

Nasdaq:BDSX

BDSX Rankings

BDSX Stock Data

184.74M
70.41M
47.12%
38.64%
0.29%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
LOUISVILLE